Log In
BCIQ
Print this Print this
 

Takecab, vonoprazan fumarate (TAK-438)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionSmall molecule potassium-competitive acid blocker
Molecular Target H+/K ATPase pump
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$196.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/27/2014

Undisclosed

$196.0M

Undisclosed

Get a free BioCentury trial today